Outcomes of CAR T-Cell therapy in relapsed/refractory multiple myeloma by race: a multicenter real-world study

Overview of attention for article published in Blood Cancer Journal, November 2025

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

news: 1 news outlet
twitter: 17 X users

bluesky: 1 Bluesky user

Readers on

mendeley: 1 Mendeley

So far, Altmetric has seen 28 X posts from 17 X users, with an upper bound of 32,280 followers.

RT @Abdallah81MD: Outcomes of CAR T-Cell therapy in relapsed/refractory multiple myeloma by race: a multicenter real-world study https://t…

Outcomes of CAR T-Cell therapy in relapsed/refractory multiple myeloma by race: a multicenter real-world study https://t.co/kTWFYOBh1Q… #mmsm #myeloma #USMIRC #MedEd #MedTwitter https://t.co/UHpmmWE3sK https://t.co/uJn8xX7sCc

RT @mumairmushtaq: Outcomes of CAR T-Cell therapy in relapsed/refractory multiple myeloma by race: a multicenter real-world study. Blood Ca…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 24 additional X posts.